The global superdisintegrants market is projected to reach US$ 659.17 Mn in 2027 from US$ 369.56 Mn in 2019. The market is projected to grow with a CAGR of 7.6% from 2020-2027.
Driving factors include growing adoption of orally disintegrating drugs, increasing acceptability of generic drugs. However, the risk high cost associated with manufacturing of superdisintegrants is expected to hamper the market during the forecast period.
Cancer is one of the major cause of human death worldwide. In recent years, the cases of cancer have been increasing tremendously and the trend is anticipated to remain the same in the upcoming years. According to the World Health Organization in 2018, approximately 9.6 million deaths across the globe were due to cancer. Furthermore, the National Cancer Institute predicted that in 2018, approximately 1,735,350 new cancer cases would be diagnosed in the US.
Generic drugs refer to qualitative and quantitative compositions of active components whose bioequivalence has been demonstrated by suitable bioavailability studies. Cost efficiency is the prominent factor that is driving the acceptance and adoption of generic drugs across the world. For instance, according to the study published in Journal of Pharmaceutical Health Care and Sciences (2015), nearly 50.0-60.0% of drug use across the world was of generic drugs. Certain benefits such as superior treatment outcomes, cost benefits, and easy availability played a major part in higher consumption of generic medications. Such higher consumption of generic medications is directly correlated to increased manufacturing of drugs. Moreover, increasing popularity of orally disintegrating drugs is likely to drive the usage of superdisintegrants in generic drugs, which will ultimately drive the growth of the global superdisintegrants market during the forecast period.
The global superdisintegrants market is segmented by type, formulation, therapeutic area, and application. Based on type, the superdisintegrants market is segmented into synthetic superdisintegrants, natural superdisintegrants and other superdisintegrants. In 2019, the synthetic superdisintegrants accounted for the largest market share in the global Superdisintegrants market by type. Synthetic disintegrants are more effective in lower concentrations as compared to starch; also they incorporate superior intragranularity Such merits of synthetic superdisintegrants are projected to drive the synthetic superdisintegrants segment in the global superdisintegrants market during the forecast period. Based on formulation, the Superdisintegrants market has been segmented into tablets and capsule. Based on therapeutic the market was segmented into gastrointestinal diseases, inflammatory diseases, neurological diseases, infectious diseases, cardiovascular diseases, oncology and other diseases. Furthermore, based on application, the market is segmented in to pharmaceuticals and nutraceuticals.
Some of the essential primary and secondary sources included in the report are the National Institute of Cancer Prevention and Research (NICPR), Asociación Española Contra el Cáncer, British Generics Manufacturers Association, Canada Foundation of Innovation, European Federation of Pharmaceutical Industries and Associations, Japan Chronic Disease Self-Management Association and others.
Reasons to Buy:
Driving factors include growing adoption of orally disintegrating drugs, increasing acceptability of generic drugs. However, the risk high cost associated with manufacturing of superdisintegrants is expected to hamper the market during the forecast period.
Cancer is one of the major cause of human death worldwide. In recent years, the cases of cancer have been increasing tremendously and the trend is anticipated to remain the same in the upcoming years. According to the World Health Organization in 2018, approximately 9.6 million deaths across the globe were due to cancer. Furthermore, the National Cancer Institute predicted that in 2018, approximately 1,735,350 new cancer cases would be diagnosed in the US.
Generic drugs refer to qualitative and quantitative compositions of active components whose bioequivalence has been demonstrated by suitable bioavailability studies. Cost efficiency is the prominent factor that is driving the acceptance and adoption of generic drugs across the world. For instance, according to the study published in Journal of Pharmaceutical Health Care and Sciences (2015), nearly 50.0-60.0% of drug use across the world was of generic drugs. Certain benefits such as superior treatment outcomes, cost benefits, and easy availability played a major part in higher consumption of generic medications. Such higher consumption of generic medications is directly correlated to increased manufacturing of drugs. Moreover, increasing popularity of orally disintegrating drugs is likely to drive the usage of superdisintegrants in generic drugs, which will ultimately drive the growth of the global superdisintegrants market during the forecast period.
The global superdisintegrants market is segmented by type, formulation, therapeutic area, and application. Based on type, the superdisintegrants market is segmented into synthetic superdisintegrants, natural superdisintegrants and other superdisintegrants. In 2019, the synthetic superdisintegrants accounted for the largest market share in the global Superdisintegrants market by type. Synthetic disintegrants are more effective in lower concentrations as compared to starch; also they incorporate superior intragranularity Such merits of synthetic superdisintegrants are projected to drive the synthetic superdisintegrants segment in the global superdisintegrants market during the forecast period. Based on formulation, the Superdisintegrants market has been segmented into tablets and capsule. Based on therapeutic the market was segmented into gastrointestinal diseases, inflammatory diseases, neurological diseases, infectious diseases, cardiovascular diseases, oncology and other diseases. Furthermore, based on application, the market is segmented in to pharmaceuticals and nutraceuticals.
Some of the essential primary and secondary sources included in the report are the National Institute of Cancer Prevention and Research (NICPR), Asociación Española Contra el Cáncer, British Generics Manufacturers Association, Canada Foundation of Innovation, European Federation of Pharmaceutical Industries and Associations, Japan Chronic Disease Self-Management Association and others.
Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Superdisintegrants market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global Superdisintegrants market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
1. Introduction
3. Research Methodology
4. Superdisintegrants - Market Landscape
5. Superdisintegrants Market - Key Dynamics
6. Superdisintegrants Market - Global Analysis
7. Superdisintegrants Market Analysis and Forecasts to 2027 - Type
8. Superdisintegrants Market Analysis and Forecasts to 2027 - Formulation
9. Superdisintegrants Market Analysis and Forecasts to 2027 - Therapeutic Area
10. Superdisintegrants Market Analysis and Forecasts to 2027 - Application
11. Superdisintegrants Market - Geographic Analysis
12. Superdisintegrants Market to 2027- Industry Landscape
13. Company Profiles
14. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ashland Inc.,
- Basf SE
- DowDupont
- JRS Pharma
- DFE Pharma
- Roquette
- Asahi Kasei Corporation
- Merck KGAA
- Corel Pharma Chem
- Avantor Performance Materials, LLC.
